No Data
Science and Technology Medicine-B (02171.HK): The abstract of CT071 has been accepted for poster presentation at the 2025 EHA Annual Meeting.
On April 29, 2023, the company Kedi Pharmaceuticals-B (02171.HK) announced that the summary of the results of the clinical trial (NCT06407947) for CT071 (an autologous CAR-T cell product targeting GPRC5D) for the treatment of newly diagnosed multiple myeloma (NDMM) has been accepted for presentation at the 2025 European Hematology Association ("EHA") annual meeting and will be published during the poster presentation session. The summary and further information will be released after 15:30 Central European Time on May 14, 2025.
Kangji Pharmaceutical-B (02171.HK) granted 3.5355 million stock options and 1.698 million restricted share units.
On April 16, 2025, Geely Pharmaceutical-B (02171.HK) announced that the company granted 3,535,500 stock options to 167 stock option recipients in accordance with the terms of the post-IPO stock option plan, subject to acceptance by the stock option recipients for it to be valid. On April 16, 2025, the company granted 1,698,000 restricted stock units to 165 restricted stock unit recipients in accordance with the terms of the post-IPO restricted stock unit plan, subject to acceptance by the restricted stock unit recipients for it to be valid.
CARSGEN-B: Annual Report 2024
Hong Kong Stock Announcement Gold Mining | CHINA OVERSEAS reported annual performance with a profit attributable to Shareholders of 15.636 billion yuan, a decrease of 38.95% year-on-year.
FOSUN PHARMA (02196) intends to invest 0.27 billion yuan to subscribe for 0.105 billion newly issued shares of UnitedHealth; Chugai Pharmaceutical-B (02171): A summary of the research results of SRK-015 injection has been accepted for an oral presentation at the 2025 ASCO Annual Meeting.
Kangji Pharmaceutical-B (02171.HK): The summary of the research results for Shureki Aolunsei injection has been accepted for an oral presentation at the 2025 ASCO Annual Meeting.
Gelonghui, March 31丨Kejiyou Pharmaceutical-B (02171.HK) announced that the study results summary of Shurekiorunai injection (Product No.: CT041, a candidate for autologous CAR-T cell therapy targeting Claudin18.2 protein) has been accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in the confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) conducted in China for advanced gastric/esophagogastric junction adenocarcinoma. The summary and further information will be available at 8:00 PM Eastern Time.
Hong Kong stock movement | Kira Pharmaceuticals-B (02171) rose nearly 7% in the afternoon, and Saikeze has begun to contribute revenue. The CT041 plan is set to submit an NDA.
Kojii Pharmaceutical-B (02171) surged nearly 7% in the afternoon, reaching a rise of 6.73% as of this report, priced at 13.32 HKD, with a transaction volume of 54.5483 million HKD.
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% Drop
